Nanobiotix Joins CAC Mid 60 and SBF 120 Indexes
Biotechnology group Nanobiotix is set to join the CAC Mid 60 and SBF 120 indexes of Euronext Paris starting December 19, 2025, according to a statement released on Sunday. This inclusion follows the annual review of indexes by the Scientific Index Committee.
Effective Date and Index Details
According to the company, the inclusion in both stock indexes will take effect after the closing of the Euronext Paris market on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 are among the most followed benchmarks for mid-sized companies and major listed companies in France, the statement notes. This decision comes from the Scientific Index Committee as part of the annual review of the samples making up the Euronext Paris indexes.
Impact on Visibility and Market Presence
The group believes that this inclusion should increase Nanobiotix's visibility among institutional investors and strengthen the company's presence on European stock markets. The admission into these indexes is also expected to increase exposure to indexed investment strategies, the statement clarifies. Laurent Levy, co-founder and chairman of the executive board, stated that this integration reflects, in his view, the ongoing confidence of financial markets in the company's long-term strategy.
About Nanobiotix
Nanobiotix is a French biotechnology company in advanced clinical development, specializing in nanoparticle-based approaches for treating patients with cancer or other diseases. Established in 2003, the company is headquartered in Paris and has been listed on Euronext Paris since 2012. It is also listed on the Nasdaq Global Select Market in New York since December 2020. The company has subsidiaries, including one in Cambridge, Massachusetts, and owns over 25 patent families related to three nanotechnology platforms, according to the statement.
